loperamide has been researched along with Diabetes Mellitus, Type 2 in 3 studies
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Selby, A | 1 |
| Reichenbach, ZW | 1 |
| Piech, G | 1 |
| Friedenberg, FK | 1 |
| Cheng, KC | 1 |
| Asakawa, A | 1 |
| Li, YX | 1 |
| Liu, IM | 1 |
| Amitani, H | 1 |
| Cheng, JT | 1 |
| Inui, A | 1 |
| Gould, M | 1 |
| Sellin, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind, Placebo Controlled, Cross Over Study to Investigate the Effectiveness and Safety of Eluxadoline in the Treatment of Diabetic Diarrhea[NCT04313088] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2022-07-01 | Withdrawn (stopped due to This study did not enroll any subjects) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for loperamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Pathophysiology, Differential Diagnosis, and Treatment of Diabetic Diarrhea.
Topics: Antidiarrheals; Autonomic Nervous System Diseases; Blind Loop Syndrome; Celiac Disease; Diabetes Mel | 2019 |
Opioid μ-receptors as new target for insulin resistance.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin Resistance; Loperamide; Mice; | 2013 |
1 other study available for loperamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Diabetic diarrhea.
Topics: Algorithms; Antidiarrheals; Celiac Disease; Clonidine; Colitis; Diabetes Complications; Diabetes Mel | 2009 |